View Post

Breast cancer: Reducing this amino acid could make drugs more effective

In In The News by Barbara Jacoby

By: Catharine Paddock PhD From: medicalnewstoday.com Leucine, an amino acid that the body needs for making protein, appears to have a surprising role in the development of resistance to tamoxifen in breast cancer that tests positive for the estrogen receptor. Scientists from Harvard Medical School, in Boston, MA, recently made this “unexpected” discovery about estrogen receptor-positive (ER-positive) breast cancer in …

View Post

Changes in Gene Expression May Hint at Relapse Risk in ER-positive Patients on Hormone Therapy, Study Finds

In In The News by Barbara Jacoby

By: Alejandra Viviescas, PhD. From: breastcancer-news.com Specific changes in gene expression might help to predict the risk of relapse in estrogen receptor (ER)-positive breast cancer patients under hormone therapy, a study reports. The study, “Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumors,” was published in Breast Cancer Research. Most ER-positive breast cancer …

View Post

‘Evil’ protein may be key in common breast cancer

In In The News by Barbara Jacoby

Source: University of Arizona From: futurity.org New research untangles some of the mysteries of a protein called EVL (pronounced “evil”), which may reduce the ability of a common kind of breast cancer to spread to other parts of the body. About 80 percent of all breast cancers are estrogen receptor-positive, in which estrogen fuels cancer growth. The new discovery could have …

View Post

Study: Men’s breast cancer tumor types differ

In In The News by Barbara Jacoby

By: Kathleen Doheny From: dailyrecord.com Men’s breast cancer differs in some ways from women’s, new research finds. One important difference is in the rates of survival. The study found that while survival for men with breast cancer has improved, it hasn’t kept pace with the strides made in treating breast cancer in women. “Although we saw a significant improvement in …